- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 576486, 8 pages
CTLA-4 Expression and Polymorphisms in Lung Tissue of Patients with Diagnosed Non-Small-Cell Lung Cancer
1Department of General and Oncological Pulmonology, 1st Chair of Internal Diseases, Medical University of Lodz, Kopcińskiego 22, 90-153 Łódź, Poland
2Department of Molecular Bases of Medicine, 1st Chair of Internal Diseases, Medical University of Lodz, Pomorska 251, 92-213 Łódź, Poland
3Department of Pneumology and Allergology, 1st Chair of Internal Diseases, Medical University of Lodz, Kopcińskiego 22, 90-153 Łódź, Poland
4Department of Chest Surgery, General and Oncological Surgery University Hospital No. 2, Medical University of Lodz, Żeromskiego 113, 90-710 Łódź, Poland
Received 23 April 2013; Revised 19 June 2013; Accepted 23 June 2013
Academic Editor: Carlo Jose Freire de Oliveira
Copyright © 2013 Adam Antczak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- V. Chew, H. C. Toh, and J. P. Abastado, “Immune microenvironment in tumor progression: characteristics and challenges for therapy,” Journal of Oncology, vol. 2012, pp. 608406–608415, 2012.
- M. L. Tsiatas, R. Gyftaki, C. Liacos et al., “Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy,” International Journal of Gynecological Cancer, vol. 19, no. 8, pp. 1329–1334, 2009.
- A. B. Frey and N. Monu, “Signaling defects in anti-tumor T cells,” Immunological Reviews, vol. 222, no. 1, pp. 192–205, 2008.
- A. H. Sharpe and A. K. Abbas, “T-cell costimulation—biology, therapeutic potential, and challenges,” The New England Journal of Medicine, vol. 355, no. 10, pp. 973–975, 2006.
- D. Nagorsen, C. Scheibenbogen, F. M. Marincola, A. Letsch, and U. Keilholz, “Natural T cell immunity against cancer,” Clinical Cancer Research, vol. 9, no. 12, pp. 4296–4303, 2003.
- R. J. Greenwald, G. J. Freeman, and A. H. Sharpe, “The B7 family revisited,” Annual Review of Immunology, vol. 23, pp. 515–548, 2005.
- J. G. Egen, M. S. Kuhns, and J. P. Allison, “CTLA-4: new insights into its biological function and use in tumor immunotherapy,” Nature Immunology, vol. 3, no. 7, pp. 611–618, 2002.
- E. Contardi, G. L. Palmisano, P. L. Tazzari et al., “CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction,” International Journal of Cancer, vol. 117, no. 4, pp. 538–550, 2005.
- X. Li, C. Zhang, J. Zhang, et al., “Polymorphisms in the CTLA-4 gene and rheumatoid arthritis susceptibility: a meta-analysis,” Journal of Clinical Immunology, vol. 32, no. 3, pp. 530–539, 2012.
- D. Pastuszak-Lewandoska, E. Sewerynek, D. Domańska, et al., “CTLA-4 gene polymorphisms and their influence on predisposition to autoimmune thyroid diseases (Graves' disease and Hashimoto's thyroiditis),” Archives of Medical Science, vol. 8, no. 3, pp. 415–421, 2012.
- S. T. Tang, H. Q. Tang, Q. Zhang, et al., “Association of cytotoxic T-lymphocyte associated antigen 4 gene polymorphism with type 1 diabetes mellitus: a meta-analysis,” Gene, vol. 508, no. 2, pp. 165–187, 2012.
- J. Benmansour, M. Stayoussef, F. A. Al-Jenaidi et al., “Association of single nucleotide polymorphisms in cytotoxic T-lymphocyte antigen 4 and susceptibility to autoimmune type 1 diabetes in Tunisians,” Clinical and Vaccine Immunology, vol. 17, no. 9, pp. 1473–1477, 2010.
- K. Zaletel, B. Krhin, S. Gaberšček, A. Biček, T. Pajič, and S. Hojker, “Association of CT60 cytotoxic T lymphocyte antigen-4 gene polymorphism with thyroid autoantibody production in patients with Hashimoto's and postpartum thyroiditis,” Clinical and Experimental Immunology, vol. 161, no. 1, pp. 41–47, 2010.
- F. K. Kavvoura, T. Akamizu, T. Awata et al., “Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 8, pp. 3162–3170, 2007.
- Y. H. Lee, J. B. Harley, and S. K. Nath, “CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis,” Human Genetics, vol. 116, no. 5, pp. 361–367, 2005.
- L. Karabon, E. Pawlak, A. Tomkiewicz et al., “CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer,” Human Immunology, vol. 72, no. 10, pp. 947–954, 2011.
- W. Wang, J. Wang, H. Song, J. Liu, B. Song, and X. Cao, “Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma,” Genetic Testing and Molecular Biomarkers, vol. 15, no. 7-8, pp. 503–506, 2011.
- J. Zheng, X. Yu, L. Jiang et al., “Association between the Cytotoxic T-Lymphocyte Antigen 4 +49G > A polymorphism and cancer risk: a meta-analysis,” BMC Cancer, vol. 10, article 522, 2010.
- Y. Zhang, J. Zhang, Y. Deng et al., “Polymorphisms in the cytotoxic T-lymphocyte antigen 4 gene and cancer risk: a meta-analysis,” Cancer, vol. 117, no. 18, pp. 4312–4324, 2011.
- R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013.
- D. Capece, D. Verzella, M. Fischietti, F. Zazzeroni, and E. Alesse, “Targeting costimulatory molecules to improve antitumor immunity,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 926321, 17 pages, 2012.
- A. Facciabene, G. T. Motz, and G. Coukos, “T-Regulatory cells: key players in tumor immune escape and angiogenesis,” Cancer Research, vol. 72, no. 9, pp. 2162–2171, 2012.
- H. Mao, L. Zhang, Y. Yang et al., “New insights of CTLA-4 into its biological function in breast cancer,” Current Cancer Drug Targets, vol. 10, no. 7, pp. 728–736, 2010.
- H. Zheng, Y. Li, X. Wang, X. Zhang, and X. Wang, “Expression and significance of gp96 and immune-related gene CTLA-4, CD8 in lung cancer tissues,” The Chinese Journal of Lung Cancer, vol. 13, no. 8, pp. 790–794, 2010.
- K. V. Shah, A. J. Chien, C. Yee, and R. T. Moon, “CTLA-4 is a direct target of Wnt/β-catenin signaling and is expressed in human melanoma tumors,” Journal of Investigative Dermatology, vol. 128, no. 12, pp. 2870–2879, 2008.
- S. Salvi, V. Fontana, S. Boccardo et al., “Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer,” Cancer Immunology, Immunotherapy, vol. 61, no. 9, pp. 1463–1472, 2012.
- T. Sun, Y. Zhou, M. Yang et al., “Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer,” Cancer Research, vol. 68, no. 17, pp. 7025–7034, 2008.
- A. Ghaderi, F. Yeganeh, T. Kalantari et al., “Cytotoxic T lymphocyte antigen-4 gene in breast cancer,” Breast Cancer Research and Treatment, vol. 86, no. 1, pp. 1–7, 2004.
- A. Hadinia, S. V. Hossieni, N. Erfani, M. Saberi-Firozi, M. J. Fattahi, and A. Ghaderi, “CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers,” Journal of Gastroenterology and Hepatology, vol. 22, no. 12, pp. 2283–2287, 2007.
- P. Qi, C.-P. Ruan, H. Wang et al., “CTLA-4 +49A>G polymorphism is associated with the risk but not with the progression of colorectal cancer in Chinese,” International Journal of Colorectal Disease, vol. 25, no. 1, pp. 39–45, 2010.
- Y.-K. Wong, K.-W. Chang, C.-Y. Cheng, and C.-J. Liu, “Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma,” Journal of Oral Pathology and Medicine, vol. 35, no. 1, pp. 51–54, 2006.
- L. Wang, D. Li, Z. Fu, H. Li, W. Jiang, and D. Li, “Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population,” BMC cancer, vol. 7, article 173, 2007.
- E. Pawlak, L. Karabon, I. Wlodarska-Polinska et al., “Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population,” Human Immunology, vol. 71, no. 2, pp. 195–200, 2010.
- T.-H. Su, T.-Y. Chang, Y.-J. Lee et al., “CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women,” Carcinogenesis, vol. 28, no. 6, pp. 1237–1240, 2007.
- K. Suwalska, E. Pawlak, L. Karabon et al., “Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population,” Human Immunology, vol. 69, no. 3, pp. 193–201, 2008.
- F. Dilmec, A. Ozgonul, A. Uzunkoy, and F. Akkafa, “Investigation of CTLA-4 and CD28 gene polymorphisms in a group of Turkish patients with colorectal cancer,” International Journal of Immunogenetics, vol. 35, no. 4-5, pp. 317–321, 2008.
- S. Anjos, A. Nguyen, H. Ounissi-Benkalha, M.-C. Tessier, and C. Polychronakos, “A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele,” Journal of Biological Chemistry, vol. 277, no. 48, pp. 46478–46486, 2002.
- T. Kouki, Y. Sawai, C. A. Gardine, M.-E. Fisfalen, M.-L. Alegre, and L. J. DeGroot, “CTLA-4 Gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease,” Journal of Immunology, vol. 165, no. 11, pp. 6606–6611, 2000.
- B. Song, Y. Liu, J. Liu et al., “CTLA-4 +49A>G polymorphism is associated with advanced non-small cell lung cancer prognosis,” Respiration, vol. 82, no. 5, pp. 439–444, 2011.
- E. V. S. Høgdall, S. K. Kjaer, E. Glud et al., “Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish “malova” ovarian cancer study,” Anticancer Research, vol. 23, no. 4, pp. 3397–3404, 2003.
- D. A. Chistiakov, K. V. Savost'anov, R. I. Turakulov, I. A. Efremov, and L. M. Demurov, “Genetic analysis and functional evaluation of the C/T(-318) and A/G(-1661) polymorphisms of the CTLA-4 gene in patients affected with Graves' disease,” Clinical Immunology, vol. 118, no. 2-3, pp. 233–242, 2006.
- S. M. Anjos, M.-C. Tessier, and C. Polychronakos, “Association of the cytotoxic T lymphocyte-associated antigen 4 gene with type 1 diabetes: evidence for independent effects of two polymorphisms on the same haplotype block,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 12, pp. 6257–6265, 2004.
- X. B. Wang, X. Zhao, R. Giscombe, and A. K. Lefvert, “A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein,” Genes and Immunity, vol. 3, no. 4, pp. 233–234, 2002.
- A. Ligers, N. Teleshova, T. Masterman, W.-X. Huang, and J. Hillert, “CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms,” Genes and Immunity, vol. 2, no. 3, pp. 145–152, 2001.
- N. Khaghanzadeh, N. Erfani, M. A. Ghayumi, and A. Ghaderi, “CTLA4 gene variations and haplotypes in patients with lung cancer,” Cancer Genetics and Cytogenetics, vol. 196, no. 2, pp. 171–174, 2010.